OrigiMed Company
OrigiMed is a medical science and technology transforming company which focuses on developing new technologies and clinical applications for all types of cancer patients. By carrying out more comprehensive and high-throughput methods, leveraging wholesome bioinformatics analysis and clinical annotation, they identify cancer specific molecular markers and genomic features to guide targeted or immuno-therapy, ultimately aiming to fortify the evolution of cancer precision medicine in China.
Founded Date:
42370
Last Funding Type:
Series B
Headquarters:
China
Investors Number:
5
Technology:
diagnostics
Employee Number:
251-500
Industry:
Health Care, Health Diagnostics
Estimated Revenue:
Less than $1M
Last Funding Date:
2018-12-20
Funding Status:
Early Stage Venture
Total Funding:
$39M